Development of tubulin polymerization inhibitors as anticancer agents

References

• Janke C, Magiera MM. The tubulin code and its role in controlling microtubule properties and functions. Nat Rev Mol Cell Biol. 2020;21(6):307–326. doi: 10.1038/s41580-020-0214-3
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Calvo E. Novel agents that target tublin and related elements. Semin Oncol. 2006;33(4):421–435. doi: 10.1053/j.seminoncol.2006.04.006
   PubMed Web of Science ®Google Scholar
• Peerzada MN, Hamel E, Bai R, et al. Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development. Pharmacol Ther. 2021;225:107860. doi: 10.1016/j.pharmthera.2021.107860
   PubMed Web of Science ®Google Scholar
• Logan CM, Menko AS. Microtubules: Evolving roles and critical cellular interactions. Exp Biol Med. 2019;244:1240–1254. doi: 10.1177/1535370219867296
   Web of Science ®Google Scholar
• Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9(10):790–803. doi: 10.1038/nrd3253
   PubMed Web of Science ®Google Scholar
• Mukhtar E, Adhami VM, Mukhtar H. Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther. 2014;13(2):275–284. doi: 10.1158/1535-7163.MCT-13-0791
   PubMed Web of Science ®Google Scholar
• Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol. 2007;18:3–8. doi: 10.1093/annonc/mdm172
   PubMed Web of Science ®Google Scholar
• Stiller CA. International patterns of cancer incidence in adolescents. Cancer Treat Rev. 2007;33(7):631–645. doi: 10.1016/j.ctrv.2007.01.001
   PubMed Web of Science ®Google Scholar
• Arnst KE, Banerjee S, Chen H, et al. Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. Med Res Rev. 2019;39(4):1398–1426. doi: 10.1002/med.21568
   PubMed Web of Science ®Google Scholar
• Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277(5698):665–667. doi: 10.1038/277665a0
   PubMed Web of Science ®Google Scholar
• Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55:2325–2333.
   PubMed Web of Science ®Google Scholar
• Nogales E, Wolf SG, Khan IA, et al. Structure of tubulin at 6.5 a and location of the taxol-binding site. Nature. 1995;375:424–427. doi: 10.1038/375424a0
   PubMed Web of Science ®Google Scholar
• Pryor DE, O’Brate A, Bilcer G, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry. 2002;41(29):9109–9115. doi: 10.1021/bi020211b
   PubMed Web of Science ®Google Scholar
• Prota AE, Bargsten K, Northcote PT, et al. Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew Chem Int Ed Engl. 2014;53(6):1621–1625. doi: 10.1002/anie.201307749
   PubMed Web of Science ®Google Scholar
• Hamel E, Day BW, Miller JH, et al. Synergistic effects of peloruside a and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol. 2006;70(5):1555–1564. doi: 10.1124/mol.106.027847
   PubMed Web of Science ®Google Scholar
• Coderch C, Morreale A, Gago F. Tubulin-based structure-affinity relationships for Antimitotic Vinca Alkaloids. Anticancer Agents Med Chem. 2012;12(3):219–225. doi: 10.2174/187152012800228841
   PubMed Web of Science ®Google Scholar
• Bai R, Nguyen TL, Burnett JC, et al. Interactions of halichondrin B and Eribulin with tubulin. J Chem Inf Model. 2011;51(6):1393–1404. doi: 10.1021/ci200077t
   PubMed Web of Science ®Google Scholar
• Avendaño C, Menéndez JC. Anticancer Drugs Targeting Tubulin and Microtubules. Med Chem Anticancer Drugs Elsevier. 2015;359–390. doi: 10.1016/B978-0-444-62649-3.00009-0
   Google Scholar
• Gigant B, Wang C, Ravelli RBG, et al. Structural basis for the regulation of tubulin by vinblastine. Nature. 2005;435(7041):519–522. doi: 10.1038/nature03566
   PubMed Web of Science ®Google Scholar
• Svoboda G, Johnson I, Gorman M, et al. Current status of research on the alkaloids of vinca rosea Linn. (catharanthus roseus G Don). J Pharm Sci. 1962;51:707–720. doi: 10.1002/jps.2600510802
   PubMed Web of Science ®Google Scholar
• Chen S-H, Hong J. Novel tubulin interacting agents: a tale of Taxus brevifolia and Catharanthus roseus-based drug discovery. Drugs Future. 2006;31:123. doi: 10.1358/dof.2006.031.02.953585
   Web of Science ®Google Scholar
• Cruz-Monserrate Z, Vervoort HC, Bai R, et al. Diazonamide a and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin. Mol Pharmacol. 2003;63(6):1273–1280. doi: 10.1124/mol.63.6.1273
   PubMed Web of Science ®Google Scholar
• Pera B, Barasoain I, Pantazopoulou A, et al. New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanism. ACS Chem Biol. 2013;8(9):2084–2094. doi: 10.1021/cb400461j
   PubMed Web of Science ®Google Scholar
• Cormier A, Marchand M, Ravelli RBG, et al. Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep. 2008;9:1101–1106. doi: 10.1038/embor.2008.171
   PubMed Web of Science ®Google Scholar
• Wang Y, Benz FW, Wu Y, et al. Structural insights into the pharmacophore of vinca domain inhibitors of microtubules. Mol Pharmacol. 2016;89(2):233–242. doi: 10.1124/mol.115.100149
   PubMed Web of Science ®Google Scholar
• Waight AB, Bargsten K, Doronina S, et al. Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics. PLoS One. 2016;11(8):0160890. doi: 10.1371/journal.pone.0160890
   Web of Science ®Google Scholar
• Bai R, Edler MC, Bonate PL, et al. Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol. 2009;75(1):218–226. doi: 10.1124/mol.108.051110
   PubMed Web of Science ®Google Scholar
• Cruz-Monserrate Z, Mullaney JT, Harran PG, et al. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. Eur J Biochem. 2003;270:3822–3828. doi: 10.1046/j.1432-1033.2003.03776.x
   PubMedGoogle Scholar
• Wieczorek M, Tcherkezian J, Bernier C, et al. The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. Sci Transl Med. 2016;8(365):365. doi: 10.1126/scitranslmed.aag1093
   Web of Science ®Google Scholar
• Bai R, Cruz-Monserrate Z, Fenical W, et al. Interaction of diazonamide a with tubulin. Arch Biochem Biophys. 2020;680:108217. doi: 10.1016/j.abb.2019.108217
   PubMed Web of Science ®Google Scholar
• Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol. 2006;70(6):1866–1875. doi: 10.1124/mol.106.026641
   PubMed Web of Science ®Google Scholar
• Doodhi H, Prota AE, Rodríguez-García R, et al. Termination of protofilament elongation by Eribulin induces lattice defects that promote microtubule catastrophes. Curr Biol. 2016;26(13):1713–1721. doi: 10.1016/j.cub.2016.04.053
   PubMed Web of Science ®Google Scholar
• Beyer CF, Zhang N, Hernandez R, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008;68(7):2292–2300. doi: 10.1158/0008-5472.CAN-07-1420
   PubMed Web of Science ®Google Scholar
• Sáez-Calvo G, Sharma A, de Asís Balaguer F, et al. Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin. Cell Chem Biol. 2017;24:737–750. doi: 10.1016/j.chembiol.2017.05.016
   PubMed Web of Science ®Google Scholar
• Prota AE, Bargsten K, Diaz JF, et al. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc Natl Acad Sci U S A. 2014;111(38):13817–13821. doi: 10.1073/pnas.1408124111
   PubMed Web of Science ®Google Scholar
• Yang J, Wang Y, Wang T, et al. Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule. Nat Commun. 2016;7(1):12103. doi: 10.1038/ncomms12103
   PubMedGoogle Scholar
• Prota AE, Setter J, Waight AB, et al. Pironetin binds covalently to αCys316 and perturbs a major Loop and helix of α-tubulin to inhibit microtubule formation. J Mol Biol. 2016;428(15):2981–2988. doi: 10.1016/j.jmb.2016.06.023
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen J, Xiao M, et al. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012;29(11):2943–2971. doi: 10.1007/s11095-012-0828-z
   PubMed Web of Science ®Google Scholar
• Aubin JE, Carlsen SA, Ling V. Colchicine permeation is required for inhibition of concanavalin a capping in Chinese hamster ovary cells. Proc Natl Acad Sci. 1975;72(11):4516–4520. doi: 10.1073/pnas.72.11.4516
   PubMed Web of Science ®Google Scholar
• Pettit GR, Singh SB, Hamel E, et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 1989;45(2):209–211. doi: 10.1007/BF01954881
   PubMedGoogle Scholar
• Dark GG, Hill SA, Prise VE, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997;57:1829–1834.
   PubMed Web of Science ®Google Scholar
• Gaspari R, Prota AE, Bargsten K, et al. Structural basis of cis- and trans-combretastatin binding to tubulin. Chem. 2017;2(1):102–113. doi: 10.1016/j.chempr.2016.12.005
   Web of Science ®Google Scholar
• Meleti VR, Esperandim VR, Flauzino LGB, et al. (±)-licarin a and its semi-synthetic derivatives: in vitro and in silico evaluation of trypanocidal and schistosomicidal activities. Acta Trop. 2020;202:105248. doi: 10.1016/j.actatropica.2019.105248
   PubMed Web of Science ®Google Scholar
• Sosa JA, Elisei R, Jarzab B, et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial. J Clin Oncol. 2011;29(15_suppl):5502–5502. doi: 10.1200/jco.2011.29.15_suppl.5502
   Web of Science ®Google Scholar
• Chase DM, Chaplin DJ, Monk BJ. The development and use of vascular targeted therapy in ovarian cancer. Gynecol Oncol. 2017;145(2):393–406. doi: 10.1016/j.ygyno.2017.01.031
   PubMed Web of Science ®Google Scholar
• Blay J-Y, Pápai Z, Tolcher AW, et al. Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(5):531–540. doi: 10.1016/S1470-2045(15)70102-6
   PubMed Web of Science ®Google Scholar
• Deng S, Krutilina RI, Hartman KL, et al. Colchicine-binding site agent CH-2-77 as a potent tubulin inhibitor suppressing triple-negative breast cancer. Mol Cancer Ther. 2022;21(7):1103–1114. doi: 10.1158/1535-7163.MCT-21-0899
   PubMed Web of Science ®Google Scholar
• Sekar P, Ravitchandirane R, Khanam S, et al. Novel molecules as the emerging trends in cancer treatment: an update. Med Oncol. 2022;39(2):20. doi: 10.1007/s12032-021-01615-6
   PubMed Web of Science ®Google Scholar
• Stengel C, Newman SP, Leese MP, et al. Class III β-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer. 2010;102(2):316–324. doi: 10.1038/sj.bjc.6605489
   PubMed Web of Science ®Google Scholar
• Waghray D, Zhang Q. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment. J Med Chem. 2018;61(12):5108–5121. doi: 10.1021/acs.jmedchem.7b01457
   PubMed Web of Science ®Google Scholar
• McLoughlin EC, O’Boyle NM. Colchicine-binding site inhibitors from chemistry to clinic: a review. Pharmaceuticals. 2020;13(1):8. doi: 10.3390/ph13010008
   Web of Science ®Google Scholar
• Sharom FJ. Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function. Front Oncol. 2014;4:4. doi: 10.3389/fonc.2014.00041
   PubMedGoogle Scholar
• Deng S, Banerjee S, Chen H, et al. SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis. Cancer Lett. 2023;555:216046. doi: 10.1016/j.canlet.2022.216046
   PubMed Web of Science ®Google Scholar
• Kang Y, Pei Y, Qin J, et al. Design, synthesis, and biological activity evaluation of novel tubulin polymerization inhibitors based on pyrimidine ring skeletons. Bioorg Med Chem Lett. 2023;84:129195. doi: 10.1016/j.bmcl.2023.129195
   PubMed Web of Science ®Google Scholar
• Laxmikeshav K, Sharma P, Palepu M, et al. Benzimidazole based bis-carboxamide derivatives as promising cytotoxic agents: design, synthesis, in silico and tubulin polymerization inhibition. J Mol Struct. 2023;1271:134078. doi: 10.1016/j.molstruc.2022.134078
   Web of Science ®Google Scholar
• Pochampally S, Hartman KL, Wang R, et al. Design, synthesis, and biological evaluation of pyrimidine dihydroquinoxalinone derivatives as tubulin colchicine site-binding agents that displayed potent anticancer activity both in vitro and in vivo. ACS Pharmacol Transl Sci. 2023;6(4):526–545. doi: 10.1021/acsptsci.2c00108
   PubMedGoogle Scholar
• Amin MM, Abuo-Rahma G-D, Shaykoon MSA, et al. Design, synthesis, cytotoxic activities, and molecular docking of chalcone hybrids bearing 8-hydroxyquinoline moiety with dual tubulin/EGFR kinase inhibition. Bioorg Chem. 2023;134:106444. doi: 10.1016/j.bioorg.2023.106444
   PubMed Web of Science ®Google Scholar
• Li G, Wu J-Q, Cai X, et al. Design, synthesis, and biological evaluation of diaryl heterocyclic derivatives targeting tubulin polymerization with potent anticancer activities. Eur J Med Chem. 2023;252:115284. doi: 10.1016/j.ejmech.2023.115284
   PubMed Web of Science ®Google Scholar
• Abdul Hussein SA, Razzak Mahmood AA, Tahtamouni LH, et al. New combretastatin analogs as anticancer agents: design, synthesis, microtubules polymerization inhibition, and molecular docking studies. Chem Biodivers. 2023;20(4):202201206. doi: 10.1002/cbdv.202201206
   Web of Science ®Google Scholar
• John SE, Sharma A, Gulati S, et al. Synthesis of cis -stilbene-based 1,2,4-triazole/1,3,4-oxadiazole conjugates as potential cytotoxic and tubulin polymerization inhibitors. New J Chem. 2023;(47):4687–4697. doi: 10.1039/D2NJ04955D
   Google Scholar
• Huo X-S, Jian X-E, Ou-Yang J, et al. Discovery of highly potent tubulin polymerization inhibitors: design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines. Eur J Med Chem. 2021;220(220):113449. doi: 10.1016/j.ejmech.2021.113449
   PubMedGoogle Scholar
• Sun Y-X, Song J, Kong L-J, et al. Design, synthesis and evaluation of novel bis-substituted aromatic amide dithiocarbamate derivatives as colchicine site tubulin polymerization inhibitors with potent anticancer activities. Eur J Med Chem. 2022;229:114069. doi: 10.1016/j.ejmech.2021.114069
   PubMed Web of Science ®Google Scholar
• Wang G, Liu W, Gong Z, et al. Design, synthesis, biological evaluation and molecular docking studies of new chalcone derivatives containing diaryl ether moiety as potential anticancer agents and tubulin polymerization inhibitors. Bioorg Chem. 2020;95:103565. doi: 10.1016/j.bioorg.2019.103565
   PubMed Web of Science ®Google Scholar
• Kode J, Kovvuri J, Nagaraju B, et al. Synthesis, biological evaluation, and molecular docking analysis of phenstatin based indole linked chalcones as anticancer agents and tubulin polymerization inhibitors. Bioorg Chem. 2020;105:104447. doi: 10.1016/j.bioorg.2020.104447
   PubMed Web of Science ®Google Scholar
• Rahimzadeh Oskuei S, Mirzaei S, Jafari-Nik MR, et al. Design, synthesis and biological evaluation of novel imidazole-chalcone derivatives as potential anticancer agents and tubulin polymerization inhibitors. Bioorg Chem. 2021;112:104904. doi: 10.1016/j.bioorg.2021.104904
   PubMed Web of Science ®Google Scholar
• Li G, Wang Y, Li L, et al. Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities. Eur J Med Chem. 2020;202:112519. doi: 10.1016/j.ejmech.2020.112519
   PubMed Web of Science ®Google Scholar
• Sana S, Tokala R, Bajaj DM, et al. Design and synthesis of substituted dihydropyrimidinone derivatives as cytotoxic and tubulin polymerization inhibitors. Bioorg Chem. 2019;93:103317. doi: 10.1016/j.bioorg.2019.103317
   PubMed Web of Science ®Google Scholar
• Diao P-C, Jian X-E, Chen P, et al. Design, synthesis and biological evaluation of novel indole-based oxalamide and aminoacetamide derivatives as tubulin polymerization inhibitors. Bioorg Med Chem Lett. 2020;30(2):126816. doi: 10.1016/j.bmcl.2019.126816
   PubMed Web of Science ®Google Scholar
• Perin N, Hok L, Beč A, et al. N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: synthesis, biological activity and computational analysis. Eur J Med Chem. 2021;211:113003. doi: 10.1016/j.ejmech.2020.113003
   PubMed Web of Science ®Google Scholar
• Romagnoli R, Oliva P, Prencipe F, et al. Design, synthesis and biological investigation of 2-anilino Triazolopyrimidines as tubulin polymerization inhibitors with anticancer activities. Pharmaceuticals. 2022;15(8):1031. doi: 10.3390/ph15081031
   Web of Science ®Google Scholar
• Oliva P, Romagnoli R, Manfredini S, et al. Design, synthesis, in vitro and in vivo biological evaluation of 2-amino-3-aroylbenzo[b]furan derivatives as highly potent tubulin polymerization inhibitors. Eur J Med Chem. 2020;200:112448. doi: 10.1016/j.ejmech.2020.112448
   PubMed Web of Science ®Google Scholar
• Romagnoli R, Oliva P, Salvador MK, et al. Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors. Eur J Med Chem. 2019;181:111577. doi: 10.1016/j.ejmech.2019.111577.
   PubMed Web of Science ®Google Scholar
• Romagnoli R, Prencipe F, Oliva P, et al. Design, synthesis and biological evaluation of 2-alkoxycarbonyl-3-anilinoindoles as a new class of potent inhibitors of tubulin polymerization. Bioorg Chem. 2020;97:103665. doi: 10.1016/j.bioorg.2020.103665
   PubMed Web of Science ®Google Scholar
• Kazan F, Yagci ZB, Bai R, et al. Synthesis and biological evaluation of indole-2-carbohydrazides and thiazolidinyl-indole-2-carboxamides as potent tubulin polymerization inhibitors. Comput Biol Chem. 2019;80:512–523. doi: 10.1016/j.compbiolchem.2019.05.002
   PubMed Web of Science ®Google Scholar
• Hawash M, Kahraman DC, Olgac A, et al. Design and synthesis of novel substituted indole-acrylamide derivatives and evaluation of their anti-cancer activity as potential tubulin-targeting agents. J Mol Struct. 2022;1254:132345. doi: 10.1016/j.molstruc.2022.132345
   Web of Science ®Google Scholar
• Spanò V, Barreca M, Rocca R, et al. Insight on [1,3]thiazolo[4,5-e]isoindoles as tubulin polymerization inhibitors. Eur J Med Chem. 2021;212:113122. doi: 10.1016/j.ejmech.2020.113122
   PubMed Web of Science ®Google Scholar
• Romagnoli R, Prencipe F, Oliva P, et al. Design, synthesis, and biological evaluation of 6-substituted Thieno[3,2- d]pyrimidine analogues as dual epidermal growth factor receptor kinase and microtubule inhibitors. J Med Chem. 2019;62(3):1274–1290. doi: 10.1021/acs.jmedchem.8b01391
   PubMed Web of Science ®Google Scholar
• Islam F, Quadery TM, Bai R, et al. Novel pyrazolo[4,3-d]pyrimidine microtubule targeting agents (MTAs): synthesis, structure–activity relationship, in vitro and in vivo evaluation as antitumor agents. Bioorg Med Chem Lett. 2021;41:127923. doi: 10.1016/j.bmcl.2021.127923
   PubMed Web of Science ®Google Scholar
• Oliva P, Romagnoli R, Cacciari B, et al. Synthesis and Biological Evaluation of Highly Active 7-Anilino Triazolopyrimidines as Potent Antimicrotubule Agents. Pharmaceutics. 2022;14(6):1191. doi: 10.3390/pharmaceutics14061191
   PubMed Web of Science ®Google Scholar
• Hawash M, Ergun SG, Kahraman DC, et al. Novel indole-pyrazole hybrids as potential tubulin-targeting agents; synthesis, antiproliferative evaluation, and molecular modeling studies. J Mol Struct. 2023;1285:135477. doi: 10.1016/j.molstruc.2023.135477
   PubMed Web of Science ®Google Scholar
• Khodyuk RGD, Bai R, Hamel E, et al. Diaryl disulfides and thiosulfonates as combretastatin A-4 analogues: synthesis, cytotoxicity and antitubulin activity. Bioorg Chem. 2020;101:104017. doi: 10.1016/j.bioorg.2020.104017
   PubMed Web of Science ®Google Scholar
• Romagnoli R, Prencipe F, Oliva P, et al. Synthesis and biological evaluation of new antitubulin agents containing 2-(3′,4′,5′-trimethoxyanilino)-3,6-disubstituted-4,5,6,7-tetrahydrothieno[2,3-c]pyridine scaffold. Molecules. 2020;25:1690. doi: 10.3390/molecules25071690
   PubMed Web of Science ®Google Scholar
• Romagnoli R, Oliva P, Salvador MK, et al. A facile synthesis of diaryl pyrroles led to the discovery of potent colchicine site antimitotic agents. Eur J Med Chem. 2021;214:113229. doi: 10.1016/j.ejmech.2021.113229
   PubMed Web of Science ®Google Scholar
• Puxeddu M, Wu J, Bai R, et al. Induction of ferroptosis in Glioblastoma and ovarian cancers by a new pyrrole tubulin assembly inhibitor. J Med Chem. 2022;65(23):15805–15818. Internet. doi: 10.1021/acs.jmedchem.2c01457
   PubMedGoogle Scholar
• Spanò V, Rocca R, Barreca M, et al. Pyrrolo[2′,3′: 3,4]cyclohepta[1,2- d][1,2]oxazoles, a new class of antimitotic agents active against multiple malignant cell types. J Med Chem. 2020;63:12023–12042. doi: 10.1021/acs.jmedchem.0c01315
   PubMed Web of Science ®Google Scholar
• Chen L, Ji T-Y, Huo X-S, et al. Rational design, synthesis and biological evaluation of novel 2-(substituted amino)-[1,2,4]triazolo[1,5-a]pyrimidines as novel tubulin polymerization inhibitors. Eur J Med Chem. 2022;244:114864. doi: 10.1016/j.ejmech.2022.114864
   PubMed Web of Science ®Google Scholar
• Sebastiani J, Puxeddu M, Nalli M, et al. RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor in vivo. Eur J Med Chem. 2023;246:114997. doi: 10.1016/j.ejmech.2022.114997
   PubMed Web of Science ®Google Scholar
• Li W, Xu F, Shuai W, et al. Discovery of novel quinoline–chalcone derivatives as potent antitumor agents with microtubule polymerization inhibitory activity. J Med Chem. 2019;62(2):993–1013. doi: 10.1021/acs.jmedchem.8b01755
   PubMed Web of Science ®Google Scholar
• Zhu H, Li W, Shuai W, et al. Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities. Eur J Med Chem. 2021;216:113316. doi: 10.1016/j.ejmech.2021.113316
   PubMed Web of Science ®Google Scholar
• Zhu H, Tan Y, He C, et al. Discovery of a novel vascular disrupting agent inhibiting tubulin polymerization and HDACs with potent antitumor effects. J Med Chem. 2022;65(16):11187–11213. doi: 10.1021/acs.jmedchem.2c00681
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Ishii C, Kamai Y, et al. Combination of antibody–drug conjugate and tubulin inhibitor. Tokyo (JP). 2021. (US2021/0290775A1).
   Google Scholar
• Peto CJ, Jablons DM, Tsang T, et al. Phthalazine derivatives as inhibitors of parp1, parp2, and/or tubulin useful for the treatment of cancer. (US10640493B2). Oakland CA USA: The regents of the University of California, Atlasmedx, Inc; 2020.
   Google Scholar
• Alami M, Provot O, Hamze A, et al. Compounds with tubulin polymerization inhibitory activity and immunomodulatory properties. (US2021/0230140A1). Saint Aubin (FR): Universite Paris Saclay; 2021.
   Google Scholar
• Wang G, Zheng S, Orleans N, et al. Anti-vasculature and anti–tubulin combretastatin analogs for treatment of cancer. (US10017475B2). New Orleans LA USA: Xavier University of Louisiana; 2018.
   Google Scholar
• Alami M, Hamze A, Brion J-D, et al. “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerization, for use in the treatment of cancer. Orsay (FR): Université Paris-Saclay; 2021.
   Google Scholar
• Torres J, Damoiseaux R, Yeates TO, et al. Tubulin-binding compounds, compositions and uses related thereto. (US10913750B2). Oakland CA (US): The Regents of the University of California; 2021.
   Google Scholar
• Zeqing B. Dual-target inhibitors of tubulin histone deacetylase and their uses. CN: Zhaoqing Medical College; 2022. (CN202210632565.6A).
   Google Scholar
• Yuxi W. (2- (1H-indole-3-yl) -1H- imidazole-4-yl) phenyl ketone compound and application thereof. CN: Guangdong Chenkang Biotechnology Co ltd; 2022. (CN114751891B).
   Google Scholar
• Xuejun Z, Yang Z, Hui Y, et al. Wuhan humanwell innovative drug res and development center limited company. “Diaryl compound as tubulin/src dual target inhibitor. CN: Wuhan Renfu Innovation Drug Res and Development Center Co Ltd; 2023. (CN116444427A).
   Google Scholar
• Alami M, Provot O, Hamze A, et al. Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties. US: Universite Paris-Saclay; 2023. (US20230203005A1).
   Google Scholar
• Huang L, Khedkar SA, Steinmetz MO, et al. Tubulin binding compounds and therapeutic use thereof. (NY) (US): BeyondSpring Pharmaceuticals, Inc; 2023. (US11633393B2).
   Google Scholar
• Krutilina KLH, Oluwalana D, Playa HC, et al. Sabizabulin, a potent orally bioavailable colchicine binding site agent, suppresses HER2+ breast cancer and metastasis. Cancers (Basel). 2022;14:5336. doi: 10.3390/cancers14215336
   PubMed Web of Science ®Google Scholar
• Dhasmana AKM, Khoja UB, Mishra S. Molecular structure, spectral analysis and chemical activity of sabizabulin: A computational study. J Mol Graph Model. 2023;125:108618. doi: 10.1016/j.jmgm.2023.108618
   PubMed Web of Science ®Google Scholar
• Bissonnette RP, Carlsbad AR, Goodenow R, et al. Combination therapies of hdac inhibitors and tubulin inhibitors. San Diego, CA, USA: HUYA BIOSCIENCE INT LLC; 2019. (US2019/0046513A1)
   Google Scholar
• Gangjee A. Substituted bicyclic pyrimidine compounds with tubulin an multiple receptor inhibition. (US10906910B2). Pittsburgh PA US A: Duquesne University of the Holy Spirit; 2021.
   Google Scholar
• Liu Z, Liu Y, Shi Y, et al. Design, synthesis, and biological evaluation of 1-methyl-1,4-dihyrdoindeno [1,2-c] pyrazole analogues as potential anticaner agents targeting tubulin colchicine binding site. (US10906910B2). Jinan Shandong CN: Act Pharma CO., LTD; 2021.
   Google Scholar